Purpose: The current body of evidence on the efficacy and safety of anti-VEGFs for macular oedema secondary to branch retinal vein occlusion (BRVO) is steadily growing as large clinical trials and observational studies are continually completed. The aim of this meta-analysis is to analyse anatomical and functional outcomes in response to anti-VEGF therapy using evidence generated from a pooled analysis of current clinical trials and observational studies. Methods: The current meta-analysis includes treatment of BRVO with aflibercept, bevacizumab and ranibizumab from randomised controlled trials and observational studies. Inclusion criteria included peer-reviewed publications with at least a 12-month follow-up period. On literature review using multiple electronic databases (PubMed, Embase and Cochrane), 22 studies met the inclusion criteria. Baseline patient characteristics, study design, sample size and 12- and 24-month change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) as measured on optical coherence tomography imaging were pooled in a meta-analysis. Data were then stratified by study design and anti-VEGF therapy in subgroup analyses. Results: A total of 1,236 eyes from 22 studies were included in this meta-analysis. Mean baseline BCVA ranged from 66 ETDRS letters (20/50 Snellen equivalent) to 35 letters (20/200 Snellen). Mean baseline CFT ranged from 406.0 to 681.0 µm. Anti-VEGF treatment demonstrated an overall mean improvement in BCVA at 12 months of 14 letters (95% CI 12.0 to 16.2, p < 0.001) and CFT reduction of 228 µm (95% CI –278.9 to –176.1, p < 0.001). The BCVA gains at 12 months were maintained to month 24 with a mean gain of 12.5 letters (95% CI 6.3 to 18.8, p < 0.001), as well as reduction of CFT of 238 µm (95% CI –336.0 to –140.2, p < 0.001). No cases of endophthalmitis or glaucoma were reported in any study. Conclusion: This meta-analysis confirms the comparable safety and efficacy of anti-VEGF therapies for patients with cystoid macular oedema secondary to BRVO. There is a need for randomised prospective comparative trials of anti-VEGF agents for BRVO.

1.
Rogers
S
,
McIntosh
RL
,
Cheung
N
,
Lim
L
,
Wang
JJ
,
Mitchell
P
, et al;
International Eye Disease Consortium
.
The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia
.
Ophthalmology
.
2010
Feb
;
117
(
2
):
313
9.e1
.
[PubMed]
0161-6420
2.
Rogers
SL
,
McIntosh
RL
,
Lim
L
,
Mitchell
P
,
Cheung
N
,
Kowalski
JW
, et al
Natural history of branch retinal vein occlusion: an evidence-based systematic review
.
Ophthalmology
.
2010
Jun
;
117
(
6
):
1094
1101.e5
.
[PubMed]
0161-6420
3.
Fraenkl
SA
,
Mozaffarieh
M
,
Flammer
J
.
Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins
.
EPMA J
.
2010
Jun
;
1
(
2
):
253
61
.
[PubMed]
1878-5077
4.
Noma
H
,
Funatsu
H
,
Mimura
T
.
Association of electroretinographic parameters and inflammatory factors in branch retinal vein occlusion with macular oedema
.
Br J Ophthalmol
.
2012
Dec
;
96
(
12
):
1489
93
.
[PubMed]
0007-1161
5.
Yoshimura
T
,
Sonoda
KH
,
Sugahara
M
,
Mochizuki
Y
,
Enaida
H
,
Oshima
Y
, et al
Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases
.
PLoS One
.
2009
Dec
;
4
(
12
):
e8158
.
[PubMed]
1932-6203
6.
Noma
H
,
Funatsu
H
,
Yamasaki
M
,
Tsukamoto
H
,
Mimura
T
,
Sone
T
, et al
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
.
Am J Ophthalmol
.
2005
Aug
;
140
(
2
):
256
61
.
[PubMed]
0002-9394
7.
Noma
H
,
Funatsu
H
,
Mimura
T
,
Eguchi
S
,
Hori
S
.
Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion
.
Am J Ophthalmol
.
2011
Oct
;
152
(
4
):
669
677.e1
.
[PubMed]
0002-9394
8.
Karia
N
.
Retinal vein occlusion: pathophysiology and treatment options
.
Clin Ophthalmol
.
2010
Jul
;
4
:
809
16
.
[PubMed]
1177-5467
9.
Kern
TS
.
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy
.
Exp Diabetes Res
.
2007
;
2007
:
95103
.
[PubMed]
1687-5214
10.
Rhoades
W
,
Dickson
D
,
Nguyen
QD
,
Do
DV
.
Management of macular edema due to central retinal vein occlusion - The role of aflibercept
.
Taiwan J Ophthalmol
.
2017
Apr-Jun
;
7
(
2
):
70
6
.
[PubMed]
2211-5056
11.
Pai
SA
,
Shetty
R
,
Vijayan
PB
,
Venkatasubramaniam
G
,
Yadav
NK
,
Shetty
BK
, et al
Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion
.
Am J Ophthalmol
.
2007
Apr
;
143
(
4
):
601
6
.
[PubMed]
0002-9394
12.
Campochiaro
PA
,
Hafiz
G
,
Shah
SM
,
Nguyen
QD
,
Ying
H
,
Do
DV
,
Quinlan
E
,
Zimmer-Galler
I
,
Haller
JA
,
Solomon
SD
,
Sung
JU
,
Hadi
Y
,
Janjua
KA
,
Jawed
N
,
Choy
DF
,
Arron
JR
:
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.
Molecular therapy : the journal of the American Society of Gene Therapy
2008
;16:791-799.
13.
Downs
SH
,
Black
N
.
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
.
J Epidemiol Community Health
.
1998
Jun
;
52
(
6
):
377
84
.
[PubMed]
0143-005X
14.
Higgins
JP
,
Thompson
SG
,
Deeks
JJ
,
Altman
DG
.
Measuring inconsistency in meta-analyses
.
BMJ
.
2003
Sep
;
327
(
7414
):
557
60
.
[PubMed]
0959-8138
15.
Higgins
JP
,
Thompson
SG
.
Quantifying heterogeneity in a meta-analysis
.
Stat Med
.
2002
Jun
;
21
(
11
):
1539
58
.
[PubMed]
0277-6715
16.
Clark
WL
,
Boyer
DS
,
Heier
JS
,
Brown
DM
,
Haller
JA
,
Vitti
R
, et al
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study
.
Ophthalmology
.
2016
Feb
;
123
(
2
):
330
6
.
[PubMed]
0161-6420
17.
Pichi
F
,
Elbarky
AM
,
Elhamaky
TR
.
Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion
.
Int Ophthalmol
.
2017
.
[PubMed]
0165-5701
18.
Wang
JK
,
Su
PY
,
Hsu
YR
,
Chen
YJ
,
Chen
FT
,
Tseng
YY
.
Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
.
J Ophthalmol
.
2016
;
2016
:
8421940
.
[PubMed]
2090-004X
19.
Bandello
F
,
Augustin
A
,
Tufail
A
,
Leaback
R
.
A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion
.
Eur J Ophthalmol
.
2018
Nov
;
28
(
6
):
697
705
.
[PubMed]
1120-6721
20.
Brynskov
T
,
Kemp
H
,
Sørensen
TL
.
Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice
.
Retina
.
2014
Aug
;
34
(
8
):
1637
43
.
[PubMed]
0275-004X
21.
Chatziralli
I
,
Theodossiadis
G
,
Chatzirallis
A
,
Parikakis
E
,
Mitropoulos
P
,
Theodossiadis
P
.
RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data
.
Retina
.
2018
Mar
;
38
(
3
):
559
68
.
[PubMed]
0275-004X
22.
Khan
M
,
Wai
KM
,
Silva
FQ
,
Srivastava
S
,
Ehlers
JP
,
Rachitskaya
A
, et al
Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice
.
Ophthalmic Surg Lasers Imaging Retina
.
2017
Jun
;
48
(
6
):
465
72
.
[PubMed]
2325-8160
23.
Rezar
S
,
Eibenberger
K
,
Bühl
W
,
Georgopoulos
M
,
Schmidt-Erfurth
U
,
Sacu
S
;
Macula Study Group Vienna
.
Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years
.
Acta Ophthalmol
.
2015
Dec
;
93
(
8
):
719
25
.
[PubMed]
1755-375X
24.
Sakanishi
Y
,
Lee
A
,
Usui-Ouchi
A
,
Ito
R
,
Ebihara
N
.
Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
.
Clin Ophthalmol
.
2016
Jun
;
10
:
1161
5
.
[PubMed]
1177-5467
25.
Shiono
A
,
Kogo
J
,
Sasaki
H
,
Yomoda
R
,
Jujo
T
,
Tokuda
N
, et al
Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab
.
PLoS One
.
2018
Jun
;
13
(
6
):
e0199552
.
[PubMed]
1932-6203
26.
Tan
MH
,
McAllister
IL
,
Gillies
ME
,
Verma
N
,
Banerjee
G
,
Smithies
LA
, et al
Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion
.
Am J Ophthalmol
.
2014
Jan
;
157
(
1
):
237
247.e1
.
[PubMed]
0002-9394
27.
Ivanovska Adjievska
B
,
Boskurt
S
,
Orovcanec
N
,
Dimovska-Jordanova
V
.
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
.
Clin Ophthalmol
.
2017
Jun
;
11
:
1183
90
.
[PubMed]
1177-5467
28.
Gokce
G
,
Sobaci
G
,
Durukan
AH
,
Erdurman
FC
.
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
.
Clin Ophthalmol
.
2014
Feb
;
8
:
355
62
.
[PubMed]
1177-5467
29.
Chatziralli
IP
,
Sergentanis
TN
,
Sivaprasad
S
.
HYPERREFLECTIVE FOCI AS AN INDEPENDENT VISUAL OUTCOME PREDICTOR IN MACULAR EDEMA DUE TO RETINAL VASCULAR DISEASES TREATED WITH INTRAVITREAL DEXAMETHASONE OR RANIBIZUMAB
.
Retina
.
2016
Dec
;
36
(
12
):
2319
28
.
[PubMed]
0275-004X
30.
Hikichi
T
,
Higuchi
M
,
Matsushita
T
,
Kosaka
S
,
Matsushita
R
,
Takami
K
, et al
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
.
Br J Ophthalmol
.
2014
Feb
;
98
(
2
):
195
9
.
[PubMed]
0007-1161
31.
Khan
MA
,
Mallika
V
,
Joshi
D
.
Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study
.
Int Ophthalmol
.
2018
Jun
;
38
(
3
):
943
9
.
[PubMed]
0165-5701
32.
Kim
M
,
Lee
DH
,
Byeon
SH
,
Koh
HJ
,
Kim
SS
,
Lee
SC
.
Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion
.
Br J Ophthalmol
.
2015
Sep
;
99
(
9
):
1271
6
.
[PubMed]
0007-1161
33.
Kornhauser
T
,
Schwartz
R
,
Goldstein
M
,
Neudorfer
M
,
Loewenstein
A
,
Barak
A
.
Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)
.
Graefes Arch Clin Exp Ophthalmol
.
2016
May
;
254
(
5
):
835
44
.
[PubMed]
0721-832X
34.
Loukianou
E
,
Brouzas
D
,
Chatzistefanou
K
,
Koutsandrea
C
.
Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion
.
Int Ophthalmol
.
2016
Feb
;
36
(
1
):
21
36
.
[PubMed]
0165-5701
35.
Papadia
M
,
Misteli
M
,
Jeannin
B
,
Herbort
CP
.
The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications
.
Int Ophthalmol
.
2014
Dec
;
34
(
6
):
1193
201
.
[PubMed]
0165-5701
36.
Rush
RB
,
Simunovic
MP
,
Aragon
AV
 2nd
,
Ysasaga
JE
.
Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion
.
Ophthalmic Surg Lasers Imaging Retina
.
2014
May-Jun
;
45
(
3
):
212
6
.
[PubMed]
2325-8160
37.
Tsagkataki
M
,
Papathomas
T
,
Lythgoe
D
,
Kamal
A
.
Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion
.
Semin Ophthalmol
.
2015
;
30
(
5-6
):
352
9
.
[PubMed]
0882-0538
38.
Tilgner
E
,
Dalcegio Favretto
M
,
Tuisl
M
,
Wiedemann
P
,
Rehak
M
.
Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion
.
Acta Ophthalmol
.
2017
Nov
;
95
(
7
):
e592
6
.
[PubMed]
1755-375X
39.
Genentech: FDA approves Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion.
2010
40.
Regeneron: REGENERON ANNOUNCES FDA APPROVAL OF EYLEA® (AFLIBERCEPT) INJECTION FOR MACULAR EDEMA FOLLOWING CENTRAL RETINAL VEIN OCCLUSION.
2012
41.
Dascalu
AM
,
Popa-Cherecheanu
A
,
Popa-Cherecheanu
M
,
Nica
A
,
Serban
D
.
“Off-label” use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions
.
Rom J Ophthalmol
.
2016
Apr-Jun
;
60
(
2
):
90
5
.
[PubMed]
2457-4325
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.